ライフサイエンスコーパス: pituitary adenoma

1 el mutation of DKC1 (DKC1(S485G)) in a human pituitary adenoma.

2 repared from a human pituitary nonfunctional pituitary adenoma.

3 eningioma tumors was higher than uptake into pituitary adenoma.

4 on 4 patients after surgical removal of the pituitary adenoma.

5 s on recent developments in the treatment of pituitary adenomas.

6 ective in the treatment of hormone-secreting pituitary adenomas.

7 eningiomas, 10 vestibular schwannomas and 31 pituitary adenomas.

8 ormone secreting and nonsecreting (NS) human pituitary adenomas.

9 endoscopic than with microscopic removal of pituitary adenomas.

10 increasingly more popular for the removal of pituitary adenomas.

11 rgeted treatment for corticotropin-secreting pituitary adenomas.

12 or growth in a mouse model of ACTH-secreting pituitary adenomas.

13 her conditions such as aseptic meningitis or pituitary adenomas.

14 an update on the diagnosis and treatment of pituitary adenomas.

15 portant for the progression of nonfunctional pituitary adenomas.

16 annoma, testicular Sertoli-cell tumours, and pituitary adenomas.

17 ction in treating patients with GH-secreting pituitary adenomas.

18 al genes with altered expression patterns in pituitary adenomas.

19 and identified as being under-represented in pituitary adenomas.

20 fashion with pttg in experimental and human pituitary adenomas.

21 emerged as promising new approaches to treat pituitary adenomas.

22 nd bFGF expression in experimental and human pituitary adenomas.

23 ses on developments in treatment options for pituitary adenomas.

24 h was used as a positive control, but not in pituitary adenomas.

25 yperplasia, pancreatic endocrine tumors, and pituitary adenomas.

26 in the development of a subgroup of sporadic pituitary adenomas.

27 s and TGF-beta-RII in normal pituitaries and pituitary adenomas.

28 e diagnoses were 19 meningiomas (0.52%), six pituitary adenomas (0.16%), five cavernous malformations

29 irm this initial report that the majority of pituitary adenomas (22 of 33; 67%) do not express GADD45

30 4 genes from the DLK1-MEG3 locus in 44 human pituitary adenomas (25 NFAs, 7 ACTH-secreting, 7 GH-secr

31 cted in four oligodendrogliomas (17.4%), one pituitary adenoma (3.2%), one meningioma (2.4%), one ast

32 A specific MEN1 mutation was detected in a pituitary adenoma and corresponding germ-line DNA in a p

33 ecretion is usually caused by a GH-secreting pituitary adenoma and leads to acromegaly - a disorder o

34 nfirmed in a validation group of 37 surgical pituitary adenomas and 11 normal pituitary glands.

35 87.5%) ACTH carcinomas, but not in 112 other pituitary adenomas and carcinomas.

36 ular basis, we investigated 11 nonfunctional pituitary adenomas and eight normal pituitary glands, us

37 xcessive hormonal production from functional pituitary adenomas and generally classify pituitary aden

38 multiple, clinically relevant parameters on pituitary adenomas and may represent a valuable therapeu

39 l distribution of pancreastatin secretion in pituitary adenomas and that the hypothalamic hormone gon

40 ), and p27 expression in normal pituitaries, pituitary adenomas, and carcinomas to analyze the possib

41 atively constant in nontumorous pituitaries, pituitary adenomas, and carcinomas, indicating that p27

42 the gene product in nontumorous pituitaries, pituitary adenomas, and carcinomas.

43 Normal pituitary, pituitary adenomas, and pituitary carcinomas all express

44 nd molecular classification of nonfunctional pituitary adenomas, and suggest that therapeutic targeti

45 , but not in normal anterior pituitary or in pituitary adenomas, and the differential expression of P

46 Pituitary adenomas are frequently encountered in practic

47 As commonly encountered, pituitary adenomas are invariably benign.

48 Although pituitary adenomas are monoclonal proliferations, somati

49 eric for Rb deficiency, invariably died from pituitary adenomas by 3 months.

50 d in normal pituitaries and in all groups of pituitary adenomas by RT-PCR, whereas PVR-1 and -3 mRNAs

51 al pituitary adenomas and generally classify pituitary adenomas by using statistical and machine lear

52 Pituitary adenomas can develop sporadically or as a part

53 Pituitary adenomas cause significant morbidity caused by

54 GF-beta1-induced apoptosis in the HP75 human pituitary adenoma cell line and that PACAP, TGF-beta1, f

55 Analysis of the cultured human pituitary adenoma cell line HP75, which expresses all th

56 An immortalized human pituitary adenoma cell line, HP75, developed in our labo

57 ted cell cycle protein p27 in the HP75 human pituitary adenoma cell line.

58 GH transcription and secretion in senescent pituitary adenoma cells and also in nonpituitary (human

59 AR-gamma is an important molecular target in pituitary adenoma cells and PPAR-gamma ligands inhibit t

60 Interestingly, in cultured pituitary adenoma cells In1-ghrelin treatment (acylated

61 Pituitary adenomas cells cultured for 7 days in defined

62 Pituitary adenomas comprise 10% of intracranial tumors a

63 Pituitary adenomas comprise a heterogeneous subset of pa

64 ogues in primary human GH- and PRL-secreting pituitary adenoma cultures.

65 and, a large anterior mediastinal mass and a pituitary adenoma during a study done to evaluate recurr

66 ounts of immunoreactive pancreastatin in all pituitary adenomas except prolactin adenomas.

67 and -3 mRNAs were expressed in all groups of pituitary adenomas, except for most prolactinomas.

68 ypes I and II binding sites in all groups of pituitary adenomas, except prolactinomas.

69 Pituitary adenomas expressing and secreting GH are invar

70 targeted therapy of clinically nonfunctional pituitary adenomas, for which there is currently no medi

71 ic pituitary adenomas from 38 patients and 1 pituitary adenoma from a familial MEN1 patient were exam

72 3-mediated senescence, likely protecting the pituitary adenoma from progression to malignancy.

73 gene in pituitary tumorigenesis, 39 sporadic pituitary adenomas from 38 patients and 1 pituitary aden

74 is receptor in normal anterior pituitary and pituitary adenomas, GHRH-R mRNA was analyzed in 2 normal

75 r methods in the diagnosis and treatment for pituitary adenomas greatly expand our ability to care fo

76 le of PACAP in regulating apoptosis in human pituitary adenomas has not previously been examined.

77 status of other genes at this locus in human pituitary adenomas has not previously been reported.

78 primary lesions included craniopharyngioma, pituitary adenoma, Hodgkin's lymphoma, ependymoma, pinea

79 sampling correctly identified ACTH-secreting pituitary adenomas in 80% of patients with proven Cushin

80 Given the link between Hh signaling and pituitary adenomas in humans, our data suggest misregula

81 We describe cells isolated from pituitary adenomas in two patients with multiple endocri

82 iterature reveals that endoscopic removal of pituitary adenoma, in the short term, does not seem to c

83 report describes the analysis of inheritable pituitary adenomas induced by expression of the human po

84 For all other pituitary adenomas, initial therapy is generally transsp

85 that transsphenoidal microscopic removal of pituitary adenomas is a well-established procedure with

86 ACTH-secreting pituitary adenomas lead to hypercortisolemia and cause s

87 used by adrenocorticotropin (ACTH)-secreting pituitary adenomas leads to hypercortisolemia predisposi

88 Pituitary adenomas may hypersecrete hormones or cause ma

89 uble null mice, on the other hand, developed pituitary adenomas, multifocal gastric neuroendocrine hy

90 in, in human normal pituitaries (n = 11) and pituitary adenomas (n = 169) revealed that expression pa

91 /secretion, cell viability and apoptosis) in pituitary adenomas (n = 74), and to compare with the res

92 Non-functioning pituitary adenomas (NFPAs) are the most frequent pituita

93 ange, 29-82 y) with clinically nonfunctional pituitary adenomas on MRI underwent preoperative imaging

94 and the most common cause in adulthood is a pituitary adenoma, or treatment with pituitary surgery o

95 Pituitary adenoma (PA) is one of the most common intracr

96 However, the potential role of LDHA in pituitary adenoma (PA) remains unknown.

97 ne tissues, including parathyroid neoplasia, pituitary adenomas, pancreatic neuroendocrine tumors, an

98 The complete resection of pituitary adenomas (PAs) is unlikely when there is an ex

99 Observations: Prevalence of pituitary adenomas ranges from 1 in 865 adults to 1 in 2

100 te that overexpression of FRalpha mRNA by NF pituitary adenomas results in production of properly fol

101 Patients with pituitary adenomas should be identified at an early stag

102 Four of 39 sporadic pituitary adenomas showed a deletion of one copy of the

103 t-term results of endoscopic and microscopic pituitary adenoma surgery.

104 markers to predict the ultimate response of pituitary adenomas to BIM-23A760.

105 ould contribute to pathogenesis of different pituitary adenomas types, and suggest that this variant

106 2 normal human pituitary glands and 16 human pituitary adenomas using in situ hybridization.

107 o assay of folate receptors in nonfunctional pituitary adenomas using preoperative (99m)Tc-folate SPE

108 tracer may have promise for the detection of pituitary adenomas, using PET.

109 S and pseudo-MS/MS methods, and subtyping of pituitary adenomas was performed by using principal comp

110 ry roles of PACAP and its receptors in human pituitary adenomas, we investigated the expression of va

111 atin on pituitary cell function, 17 cultured pituitary adenomas were examined for immunoreactive panc

112 uence and mRNA levels appear normal in human pituitary adenomas while p27 protein levels are decrease

113 tuitary tumors, and in 23 of 26 GH-producing pituitary adenomas with high PTTG levels, senescence was